A recurring theme at the conference was: Will value investing ever rebound? Is a reversion to the mean forthcoming or has the market fundamentally changed during the past decade?
Morningstar's director of equity strategies Katie Reichart posed those questions--and many others--to two fund managers who've proved adept at valuing companies relative to their growth prospects: Giroux, who manages Gold-rated T. Rowe Price Capital Appreciation (PRWCX), and Hynes, who leads Gold-rated Vanguard Health Care (VGHCX).
To view this article, become a Morningstar Basic member.
Susan Dziubinski does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.